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Abstract 
Review on SLC19A3, with data on DNA/RNA, on 
the protein encoded and where the gene is 
implicated. 
Identity 
Other names: BBGD, THMD2, THTR2 
HGNC (Hugo): SLC19A3 
Location: 2q36.3 
Local order 
According to the NCBI Homo sapiens Annotation 
Release 106, SLC19A3 is flanked by genes 
including: ArfGAP with FG repeats 1 (AGFG1), 
microRNA 5703 (MIR5703), chromosome 2 open 
reading frame 83 (C2orf83), 5S ribosomal 
pseudogene 121 (RNA5SP121), and small nuclear 
ribonucleoprotein polypeptide G pseudogene 8 
(SNRPGP8). 
DNA/RNA 
Description 
The human SLC19A3 gene spans 32.9 kb of 
genomic DNA and is comprised of 8 exons. 
Orthologs of SLC19A3 are found in 47 different 
organisms. 
Transcription 
5 transcript variants for SLC19A3 are described 
from the NCBI Homo sapiens Annotation Release 
106. NM_025243 (GenBank accession #) represents 
the main transcript (6 exons, 3775 bp) that encodes 
a peptide of 496 amino acids (Thiamine transporter-
2, THTR-2). The remaining 4 variants were 
identified from computational annotation and 
include XM_005246871 (3836 bp, 6 exons, 546 aa), 
XM_005246874 (3288 bp, 7 exons, 492 aa), 
XM_006712779 (3210 bp, 6 exons, 501 aa) and 
XM_005246875 (1257 bp, 4 exons, 383 aa). The 
stimulating protein-1 (SP1)/ guanosine cytidine 
(GC) box has been identified in the thiamine-
responsive region of SLC19A3 promoter, and SP1 
transcriptional factor was reported for regulating 
THTR-2 expression in response to extracellular 
thiamine level (Nabokina et al., 2013). 
Pseudogene 
Two SLC19A3-related pseudogenes have been 
reported, namely LOC100130121 locating at 
chromosome 7p11, and LOC100420667 locating at 
chromosome 2q37. 
Genes flanking SLC19A3 on chromosome 2q37. The red box indicates the position and orientation of SLC19A3. 
SLC19A3 (solute carrier family 19 (thiamine transporter), 
member 3) 
Kwong A, et al. 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2015; 19(6) 402 
 
 
The exon/intron structure of SLC19A3 gene (green) and its transcript variants (blue). The coding sequences and 
untranslated regions are indicated by filled and empty boxes, respectively. 
 
Protein 
Note 
The protein product of SLC19A3 gene is often 
referred as thiamine transporter-2 (THTR-2). 
Description 
A thiamine transporter protein of 496 amino acid 
residues, 56 kDa, containing 12 transmembrane 
domains, and cytosolic N- and C-terminals (Eudy et 
al., 2000). 
Expression 
SLC19A3 expression has been widely detetced in 
human tissues including brain, heart, gastrointestinal 
tract, lung, pancreas, muscle, ovary, testis, adrenal 
gland, with the highest levels observed in placenta, 
liver and kidney (Eudy et al., 2000). A more 
restricted pattern of SLC19A3 expression was found 
in mouse tissues, including only brain, heart, lung, 
kidney and small intestine. 
Localisation 
Plasma membrane. In polarized intestinal epithelial 
cells, THTR-2 are restrictedly localized at the apical 
membrane domain (Subramanian et al., 2006a). 
Function 
THTR-2 mediates the transmembrane uptake of 
thiamine (vitamin B1) via a proton anti-port 
mechanism (Rajgopal et al., 2001). This thiamine 
uptake process was reported to be temperature-, 
energy- and pH-dependent (Ashokkumar et al., 
2006; Subramanian et al., 2007), and is adaptively 
regulated by the extracellular thiamine level through 
transcriptional regulation of the SLC19A3 gene 
(Nabokina et al., 2013). In human intestinal 
epithelial cells, THTR-2 interacts with the human 
transmembrane 4 super-family 4 (TM4SF4) and 
influences the intestinal thiamine uptake 
(Subramanian et al., 2014). 
Homology 
THTR-2 protein belongs to the SLC19 gene family 
(folate/thiamine transporter family) of solute 
carriers. Two other members of the family are 
SLC19A1 (a folate transporter) and SLC19A2 (a 
thiamine transporter, THTR-1), which share 42%  
and 53% amino acid sequence identities to the 
human THTR-2 (Ganapathy et al., 2004). The 
human SLC19A3 gene is conserved in chimpanzee, 
Rhesus monkey, dog, cow, mouse, rat, chicken, 
zebrafish, fruit fly, and mosquito. 
Mutations 
Germinal 
Mutations in SLC19A3 (homozygous and 
compound heterozygous) have been associated with 
different neurological disorders, including biotin 
responsive basal ganglia disease (BBGD), 
Wernicke's-like encephalopathy, and Leigh 
syndrome. The pathogenic mutations identified to 
date include p.Gly23Val, p.Thr422Ala (Zeng et al., 
2005), p.Lys44Glu, p.Glu320Gln (Kono et al., 2009; 
Yamada et al., 2010), c.74dupT, IVS3-14A>G (Debs 
et al., 2010), p.Ser7* (Gerards et al., 2013), 
p.Gln393*, p.Ser181Pro, p.Leu385Arg, p.Tyr169*, 
p.Ser176Tyr, p.Val299fs and p.Ser444Arg 
(Kevelam et al., 2013). 
Implicated in 
Breast cancer 
Note 
SLC19A3 expression was downregulated in breast 
cancer tumors as compared to the normal tissues (Ng 
et al., 2011). Exogenous expression of SLC19A3 in 
breast cancer cells resulted in an increased 
sensitivity to doxorubicin- and radiation-induced 
apoptosis (Liu et al., 2003), and modulated the gene 
expression associated with prostaglandin 
metabolism (Liu et al., 2004). 
Gastric cancer 
Note 
Hypermethylation of SLC19A3 promoter was 
detected in gastric cancer cell lines and carcinoma 
tissues, which led to the epigenetic downregulation 
of SLC19A3 expression (Liu et al., 2009). The 
methylation status of SLC19A3 promoter was  
further validated in plasma samples of breast and 
gastric cancer patients, suggesting it as a potential 
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blood biomarker for cancer diagnosis (Ng et al., 
2011). 
Biotin-responsive basal ganglia 
disease 
Note 
Biotin-responsive basal ganglia disease (BBGD) is a 
recessive metabolic disorder caused by the 
homozygous or compound heterozygous mutations 
in SLC19A3 (Zeng et al., 2005; Debs et al., 2010). 
Functional study of SLC19A3 [p.Gly23Val and 
p.Thr422Ala] mutants demonstrated that these 2 
mutations did not affect THTR-2 protein trafficking 
to the apical membrane, but resulting in impaired 
thiamine transport activity (Subramanian et al., 
2006b). 
Leigh syndrome 
Note 
Mutational dysfunction of SLC19A3 has been 
reported to be associated with Leigh syndrome. A 
nonsense mutation (c.20C>A; p.Ser7*) has been 
detected in SLC19A3, and was described as a 
founder mutation in the Moroccan population 
(Gerards et al., 2013). 
Wernicke's-like encephalopathy 
Note 
Compound mutations in SLC19A3 [p.Lys44Glu and 
p.Glu320Gln] were reported in patients with 
Wernicke's-like encephalopathy.  
From the expression study, p.Lys44Glu mutantion 
resulted in impaired THTR-2 intracellular transport, 
whereas the p.Glu320Gln mutant showed normal 
cell surface localization but a significiantly 
decreased thiamine uptake activity (Kono et al., 
2009). 
Apoptosis 
Note 
THTR2-transfected breast cancer cells were found 
an increase in sensitivity to chemotherapy agent 
doxorubicin and ionizing radiation, and an increase 
in apoptosis involving the caspase-3-dependent 
pathway (Liu et al., 2003). 
Diabetic nephropathy 
Note 
SLC19A3 expression was demonstrated to be down-
regulated in kidney proximal tubular epithelium 
under high glucose concentration, which led to the 
impaired renal re-uptake of thiamine, and producing 
thiamine insufficiency. This implies a novel 
mechanism of renal thiamine mishandling linked to 
the development of diabetic nephropathy (Larkin et 
al., 2012). 
Biotin deficiency 
Note 
SLC19A3 expression was found to be strikingly 
repressed in human leukocytes upon marginal biotin 
deficiency, suggesting it as a potential indicator of 
biotin status (Vlasova et al., 2005). 
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